41G微针视网膜下重组人组织纤溶酶原激活剂注射治疗黄斑下出血1例  

Subretinal Recombinant Human Tissue Plasminogen Activator Injection Using a 41G Needle for the Management of Submacular Hemorrhages: A Case Report

作　　者：陈旭峰 梁先军[2] 

机构地区：[1]暨南大学附属爱尔眼科医院,广东 广州 [2]佛山爱尔眼科医院综合眼病科,广东 广州

出　　处：《临床医学进展》2024年第8期1656-1661,共6页Advances in Clinical Medicine

摘　　要：黄斑下出血是位于视网膜光感受器细胞层和视网膜色素上皮层(retinal pigment epithelium, RPE)之间的出血,可能由年龄相关性黄斑变性(age-related macular degeneration, AMD)、视网膜大动脉瘤等疾病引起。血凝块释放的铁对感光细胞、视网膜循环等都具有毒性作用,因此血凝块的吸收快慢是预后良好与否的关键,利用41号(41G)微针行视网膜下注射人组织纤溶酶原激活剂(tissue plasminogen activator, t-PA)联合玻璃体切除术(pars plana vitrectomy, PPV)和气体填塞术能更有效、更安全地治疗视网膜下出血,从而快速吸收血凝块以保护视功能。现报道1例利用41G微针在视网膜下注射重组人组织纤溶酶原激活剂以治疗黄斑下出血。Submacular hemorrhage is bleeding between the retinal pigment epithelium (RPE) and the photoreceptor cell layer of the retina. It can be caused by age-related macular degeneration (AMD), large aneurysms of the retina and other diseases. The iron released by blood clots has toxic effects on photoreceptor cells and retinal circulation, so the absorption rate of blood clots is the key to good prognosis. Subretinal injection of human tissue plasminogen activator was performed using 41 (41G) microneedles, the combination with pars plana vitrectomy (PPV) and gas tamponage can more effectively and safely treat subretinal bleeding, thereby rapidly absorbing the blood clot to preserve visual function. We report a case of submacular hemorrhage treated by subretinal injection of recombinant human tissue plasminogen activator using 41G microneedles.

关 键 词：视网膜下注射 重组组织纤溶酶原激活剂 黄斑下出血 

分 类 号：R73[医药卫生—肿瘤]